C5-specific antibodies for the treatment of inflammatory diseases

US6355245B1 · kind B1 · utility

Assignee

• Alexion Pharmaceuticals, Inc. · US

Inventors

• Mark Evans · Fort Lee, US
• Louis A. Matis · Southport, US
• Eileen Elliott Mueller · Old Lyme, US
• Steven H. Nye · New York, US
• Scott Rollins · Monroe, US
• Russell P. Rother · Choctaw, US
• Jeremy P. Springhorn · Guilford, US
• Stephen P. Squinto · Dobbs Ferry, US
• Thomas C. Thomas · Madison, US
• James Wilkins · Woodbridge, US

Key dates

• Filing date: Jun 7, 1995
• Grant date: Mar 12, 2002
• Expiry date: Jun 7, 2015

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.